ReviewMolecular medicine (Cambridge, Mass.)2015
Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy.
Review in Molecular medicine (Cambridge, Mass.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- The Effect of Estrogen-Related Genetic Variants on the Development of Uterine Leiomyoma: Meta-analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2022Pooled it
- Estrogen is Coupled to the Calcium Release Machinery in Human Leiomyoma Cells.bioRxiv : the preprint server for biology · 2026Article
- Cytotoxic and molecular effects of S-allylcysteine on uterine leiomyoma primary culture cells.Molecular biology reports · 2026Article
- Dysregulation of PI3K/AKT signaling pathway in uterine leiomyoma: paired tissue-specific in-situ analysis.Molecular biology reports · 2026Article
- Quercetin Suppresses Uterine Leiomyoma Progression by Modulating METTL3-Mediated MAPK Signaling.International journal of molecular sciences · 2026Article
- Phytotherapeutic Intervention in Monosodium Glutamate-Induced Uterine Dysfunction: Efficacy ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Beyond VEGF and TGF-β: A Comprehensive Review of Growth Factor Pathways in the Pathophysiology of Uterine Leiomyomas.Biology · 2026Review
- Targeting steroid receptor coactivators for the treatment of benign female reproductive disorders.Endocrine connections · 2025Review
- Regional Proteomic Characterization of Uterine Leiomyomas: Implications for Molecular Pathways and Tumor Biology.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Modeling Uterine Fibroids Using Bioengineered Hydrogels.ACS biomaterials science & engineering · 2025Article
- Nutrition and Uterine Fibroids: Clinical Impact and Emerging Therapeutic Perspectives.Journal of clinical medicine · 2025Review
- Utilising Human Myometrial and Uterine Fibroid Stem Cell-Derived Three Dimentional Organoids as a Robust Model System for Understanding the Pathophysiology of Uterine Fibroids.Cell proliferation · 2025Article
- Review
- A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleeding.Communications medicine · 2025Article
- Fibroblast growth factors and endometrial decidualization: models, mechanisms, and related pathologies.Journal of Zhejiang University. Science. B · 2025Review
- BMAL1 Regulates Collagen Production in the Myometrium and Leiomyomas.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Loss of PRICKLE1 leads to subfertility, aberrant extracellular matrix and abnormal myometrial architecture in mice.Reproduction (Cambridge, England) · 2025Article
- Differential Expression of Small Non-Coding RNAs in Uterine Leiomyomas.International journal of molecular sciences · 2025Article
- The Role of Curcumin in Preventing Naturally Occurring Leiomyoma in the Galline Model.Pharmaceuticals (Basel, Switzerland) · 2024Article
- HMGA2 overexpression induces plasticity in myometrial cells and a transcriptomic profile more similar to that of uterine fibroids.F&S science · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Uterine leiomyomas are the most common tumors of the female genital tract, affecting 50% to 70% of females by the age of 50. Despite their prevalence and enormous medical and economic impact, no effective medical treatment is currently available. This is, in part, due to the poor understanding of their underlying pathobiology. Although they are thought to start as a clonal proliferation of a single myometrial smooth muscle cell, these early cytogenetic alterations are considered insufficient for tumor development and additional complex signaling pathway alterations are crucial. These include steroids, growth factors, transforming growth factor-beta (TGF-β)/Smad; wingless-type (Wnt)/β-catenin, retinoic acid, vitamin D, and peroxisome proliferator-activated receptor γ (PPARγ). An important finding is that several of these pathways converge in a summative way. For example, mitogen-activated protein kinase (MAPK) and Akt pathways seem to act as signal integrators, incorporating input from several signaling pathways, including growth factors, estrogen and vitamin D. This underlines the multifactorial origin and complex nature of these tumors. In this review, we aim to dissect these pathways and discuss their interconnections, aberrations and role in leiomyoma pathobiology. We also aim to identify potential targets for development of novel therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.